Lantheus' Investigational DVT Imaging Agent LNTH-2513 Wins SNMMI Image of the Year, Shows High Diagnostic Accuracy
LNTH has more than doubled off its 52-week low of $47.25.
Summary
Lantheus' investigational PET/CT agent, LNTH-2513, was awarded SNMMI's Image of the Year, accompanied by positive investigator-initiated trial results. The study in 46 patients demonstrated high diagnostic accuracy for proximal deep vein thrombosis (DVT), with 95% sensitivity and 92% specificity, and the agent was well tolerated. This recognition and early positive data for LNTH-2513 highlight its potential to advance DVT visualization and adds a promising candidate to Lantheus' pipeline.
At the time of this announcement, LNTH was trading at $97.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $47.25 to $103.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.